Treatment of USP19‐deficient GBM cells with TMZ reduces the colonic formation capacity and reduces proliferation in a heterotopic xenograft mouse model showing the increased effectiveness of TMZ treatment. This evidence concerns the gene USP19 and glioblastoma.